Oxytocin vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Oxytocin
Endogenous 9-amino acid neuropeptide produced in the hypothalamus with roles in social bonding, trust, and childbirth. Research applications span wound healing, anti-inflammatory effects, sexual function, anxiety reduction, and autonomic nervous system regulation. Intranasal administration crosses the blood-brain barrier and is the primary research route for behavioral and neurological applications.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| Oxytocin | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | OT, Pitocin, Syntocinon, trust hormone, bonding peptide | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Intranasal spray, Subcutaneous injection, Intravenous (clinical) | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Nausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect) | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Oxytocin is research-stage, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical); Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Dosing units differ: Oxytocin is dosed in IU, Vasoactive Intestinal Peptide (VIP) in mcg — they operate at different scales.
- Frequency: Oxytocin is typically Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols; Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
How each works
Oxytocin
Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.